hydroxychloroquine has been researched along with Venous Thromboembolism in 9 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Venous Thromboembolism: Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 8.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Utilizing an orthotopic murine PDA model in C57/Bl6 mice and patient correlative samples, we studied the role of NETs in PDA hypercoagulability and targeted this pathway through treatment with the NET inhibitor chloroquine." | 7.88 | Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. ( Boone, BA; Doerfler, WR; Ellis, JT; Liang, X; Lotze, MT; Miller-Ocuin, J; Murthy, P; Neal, MD; Ross, MA; Sperry, JL; Wallace, CT; Zeh, HJ, 2018) |
| "We evaluated the potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events among patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA)." | 4.31 | Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. ( Avina-Zubieta, JA; Choi, H; Esdaile, JM; Jorge, A; Lacaille, D; Lu, N, 2023) |
| "Utilizing an orthotopic murine PDA model in C57/Bl6 mice and patient correlative samples, we studied the role of NETs in PDA hypercoagulability and targeted this pathway through treatment with the NET inhibitor chloroquine." | 3.88 | Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. ( Boone, BA; Doerfler, WR; Ellis, JT; Liang, X; Lotze, MT; Miller-Ocuin, J; Murthy, P; Neal, MD; Ross, MA; Sperry, JL; Wallace, CT; Zeh, HJ, 2018) |
| " Subcutaneous administration of methotrexate was more effective than the oral administration at the same dosage in patients suffering from active rheumatoid arthritis." | 3.74 | [What's new in internal medicine?]. ( Francès, C, 2008) |
| " However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence." | 2.72 | COVID-19 and Its Implications for Thrombosis and Anticoagulation. ( Berkman, SA; Tapson, VF, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Perrella, A | 1 |
| Orlando, V | 1 |
| Trama, U | 1 |
| Bernardi, FF | 1 |
| Menditto, E | 1 |
| Coscioni, E | 1 |
| He, M | 1 |
| Pawar, A | 1 |
| Desai, RJ | 1 |
| Glynn, RJ | 1 |
| Lee, H | 1 |
| Weinblatt, ME | 1 |
| Solomon, DH | 1 |
| Kim, SC | 1 |
| Jorge, A | 1 |
| Lu, N | 1 |
| Choi, H | 1 |
| Esdaile, JM | 1 |
| Lacaille, D | 1 |
| Avina-Zubieta, JA | 1 |
| Kang, Y | 1 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Kow, CS | 1 |
| Hasan, SS | 1 |
| Berkman, SA | 1 |
| Tapson, VF | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Boone, BA | 1 |
| Murthy, P | 1 |
| Miller-Ocuin, J | 1 |
| Doerfler, WR | 1 |
| Ellis, JT | 1 |
| Liang, X | 1 |
| Ross, MA | 1 |
| Wallace, CT | 1 |
| Sperry, JL | 1 |
| Lotze, MT | 1 |
| Neal, MD | 1 |
| Zeh, HJ | 1 |
| Francès, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Preoperative Gemcitabine in Combination With Oral Hydroxychloroquine (GcHc) in Subjects With High Risk Stage IIb or III Adenocarcinoma of the Pancreas[NCT01128296] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine[NCT01978184] | Phase 2 | 104 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Median number of months of disease-free survival for participants receiving study treatment. (NCT01128296)
Timeframe: Up to 30 months
| Intervention | months (Median) |
|---|---|
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day) | 11.97 |
Number of Participants at each dose level of HCQ that experienced a Dose Limiting Toxicity (DLT). (NCT01128296)
Timeframe: Up to 31 days
| Intervention | participants (Number) |
|---|---|
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (200 mg/Day) | 0 |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (400 mg/Day) | 0 |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (600 mg/Day) | 0 |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (800 mg/Day) | 0 |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1000 mg/Day) | 0 |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (1200 mg/Day) | 0 |
Median number of months of overall survival for participants receiving study treatment. (NCT01128296)
Timeframe: Up to 35 months
| Intervention | months (Median) |
|---|---|
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 34.83 |
Number of participants that underwent a resection with microscopically margin-negative resection in which no gross or microscopic tumor remains in the primary tumor bed (24) / number of that completed treatment (31) (NCT01128296)
Timeframe: Up to 30 months
| Intervention | percentage of participants (Number) |
|---|---|
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 77 |
Median number of months of disease-free survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from >0 to 225%. Per participant decreases in Ca 19-9 ranged from >0 to 100%. (NCT01128296)
Timeframe: Up to 30 months
| Intervention | months (Median) | |
|---|---|---|
| Ca 19-9 Response | No Ca 19-9 Response | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 21.4 | 6.9 |
Median number of months of disease-free survival in participants who did and did not experience response to HCQ treatment. Patients who had >51 % increase in their LC3-II staining were classified as having a response to HCQ. (NCT01128296)
Timeframe: Up to 30 months
| Intervention | months (Median) | |
|---|---|---|
| Response to HQC treatment | No response to HQC treatment | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 15.03 | 6.9 |
(NCT01128296)
Timeframe: Up to 35 months
| Intervention | months (Median) | |
|---|---|---|
| p53 WT | p53 Mutant | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 21.4 | 11.8 |
Median number of months of overall survival for participants who experienced Ca 19-9 (surrogate biomarker) response (either an increase or decrease in Ca 19-9), or, no Ca 19-9 response. Per participant increases in Ca 19-9 ranged from >0 to 225%. Per participant decreases in Ca 19-9 ranged from >0 to 100%. (NCT01128296)
Timeframe: Up to 35 months
| Intervention | months (Median) | |
|---|---|---|
| Ca 19-9 Response (increase or decrease) | No Ca 19-9 Response | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 34.8 | 8.8 |
(NCT01128296)
Timeframe: Up to 35 months
| Intervention | months (Median) | |
|---|---|---|
| p53 WT | p53 Mutant | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | NA | 26.1 |
Median number of months of overall survival in participants who did and did not experience response to HCQ treatment. Patients who had >51 % increase in their LC3-II staining were classified as having a response to HCQ. (NCT01128296)
Timeframe: Up to 35 months
| Intervention | months (Median) | |
|---|---|---|
| Response to HQC treatment | No response to HQC treatment | |
| Preoperative Gemcitabine (1500 mg/m^2) + HCQ (≤1200 mg/Day) | 34.83 | 10.83 |
The mean age of patients at the time of diagnosis of disease (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment
| Intervention | years (Mean) |
|---|---|
| Gemcitabine + Abraxane | 63.6 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 66.1 |
Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale) (NCT01978184)
Timeframe: Prior to treatment (average 73.3 +/- 9.9 days prior to surgery)
| Intervention | units per milliliter (U/mL) (Mean) |
|---|---|
| Gemcitabine + Abraxane | 351.820 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 1534.633 |
Levels of Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel measured in the serum (original scale). (NCT01978184)
Timeframe: After treatment (50-67 days post treatment/surgery)
| Intervention | units per milliliter (U/mL) (Mean) |
|---|---|
| Gemcitabine + Abraxane | 319.079 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 1696.710 |
Tumor size as measured via computerized tomography (CT) scan (as a variable in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment
| Intervention | centimeters (Mean) |
|---|---|
| Gemcitabine + Abraxane | 2.562069 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 2.543056 |
The proportion of participants with positive (disease) lymph nodes involvement. (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)
| Intervention | proportion of participants (Number) |
|---|---|
| Gemcitabine + Abraxane | 0.8 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 0.561 |
The proportion of participants having resection for cure or complete remission, in which the surgical margins are negative for tumor cells. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)
| Intervention | proportion of participants (Mean) |
|---|---|
| Gemcitabine + Abraxane | 0.7 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 0.829 |
The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero. (NCT01978184)
Timeframe: Prior to treatment
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Age-Adjusted CCI=2 | Age-Adjusted CCI=3 | Age-Adjusted CCI=4 | Age-Adjusted CCI=5 | Age-Adjusted CCI=6 | Age-Adjusted CCI=7 | Age-Adjusted CCI=8 | |
| Gemcitabine + Abraxane | 3 | 5 | 7 | 8 | 5 | 2 | 0 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 1 | 2 | 11 | 15 | 8 | 2 | 2 |
"The number of participants in cancer diagnosis stage groups. Stage 0: cancer hasn't spread to nearby tissues/located in the same of origin.Stage I: cancers hasn't grown deeply into nearby tissues or spread to lymph nodes or other parts of the body. Stage II and III: cancers have grown more deeply into nearby tissues (may have metastasized to lymph nodes but not other parts of the body). Stage IV: most advanced stage (metastatic cancer) ; cancer has spread to other parts of the body. Stages subdivided further into the categories A (less agressive disease) and B (more advanced cancer). Example: stage IIA is less aggressive than stage IIB, but stage IIIA is more aggressive than stage IIB. (Stage variable used in the proportional odds logistic regression, secondary analysis of Evans Grade)." (NCT01978184)
Timeframe: Baseline - At the time of diagnosis, prior to treatment
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| IA | IB | IIA | IIB | Not Available | |
| Gemcitabine + Abraxane | 0 | 5 | 6 | 19 | 0 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 2 | 1 | 11 | 20 | 7 |
The number of patients who exhibited an Evans grade Histologic response (I, IIA, IIB, or III) to pre-operative gemcitabine / nab-paclitaxel. Histological response validated scoring system by Evans is as follows: Grade I: 1-9% tumor destruction, Grade II: 10 - 90%, Grade III: >90% tumor destruction (Grade IIA = 10-50% of tumor cells destroyed; Grade IIB = 50-90% of tumor cells destroyed), Grade IV: Absence of viable tumor cells. (NCT01978184)
Timeframe: Up to 4 years
| Intervention | number of participants (Number) | |||
|---|---|---|---|---|
| Evans grade - I | Evans grade - IIA | Evans grade - IIB | Evans grade - III | |
| Gemcitabine + Abraxane | 10 | 17 | 3 | 0 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 7 | 12 | 13 | 9 |
The number of participants who had robotic resection surgery. (Robotic surgery variable used in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Yes - robotic surgical resection procedure | No - not robotic surgical resection procedure | |
| Gemcitabine + Abraxane | 8 | 22 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 10 | 31 |
The number of participants in having each type of surgical resection procedure: Celiac Axis Resection With Distal Pancreatectomy (DPCAR) (Modified Appleby), Distal Pancreatectomy, Total Pancreatectomy, or Whipple. (Operation variable used in the proportional odds logistic regression, secondary analysis of Evans Grade). (NCT01978184)
Timeframe: At the time of surgery (≥2 weeks and ≤6 weeks post chemotherapy)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| DPCAR | Distal Pancreatectomy | Total Pancreatectomy | Whipple | |
| Gemcitabine + Abraxane | 2 | 3 | 1 | 24 |
| Gemcitabine + Abraxane and Hydroxychloroquine | 0 | 5 | 0 | 36 |
2 reviews available for hydroxychloroquine and Venous Thromboembolism
| Article | Year |
|---|---|
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Topics: Adenosine Monophosphate; Alanine; Ambulatory Care; Antibodies, Antiphospholipid; Antibodies, Monoclo | 2021 |
7 other studies available for hydroxychloroquine and Venous Thromboembolism
| Article | Year |
|---|---|
Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; | 2021 |
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
Topics: Aged; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Hydroxychloroquine; Incidence; Male; Me | 2021 |
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Case-Control Studies; Humans; Hydroxy | 2023 |
Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.
Topics: Anticoagulants; Colchicine; COVID-19 Drug Treatment; Heparin; Humans; Hydroxychloroquine; Methotrexa | 2021 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.
Topics: Adenocarcinoma; Animals; Chloroquine; DNA; Extracellular Traps; Female; Humans; Hydrolases; Hydroxyc | 2018 |
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.
Topics: Adenocarcinoma; Animals; Chloroquine; DNA; Extracellular Traps; Female; Humans; Hydrolases; Hydroxyc | 2018 |
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.
Topics: Adenocarcinoma; Animals; Chloroquine; DNA; Extracellular Traps; Female; Humans; Hydrolases; Hydroxyc | 2018 |
Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps.
Topics: Adenocarcinoma; Animals; Chloroquine; DNA; Extracellular Traps; Female; Humans; Hydrolases; Hydroxyc | 2018 |
[What's new in internal medicine?].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Bacteriophages; Body Mass | 2008 |